SELLAS Life Sciences
SLS | NASDAQ
$7.47
-$0.39 (-4.96%)
At close: Nov 16, 2026, 4:00 PM ET
$7.99
+$0.52 (+6.96%)
After-hours:
Nov 16, 2026, 7:59 PM ET
SELLAS Life Sciences Company Profile
Company profile explainedCompany Profile
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Angelos Stergiou | Founder, President, Chief Executive Officer & Director |
| John Thomas Burns | Senior Vice President & Chief Financial Officer |
| Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality |
| Dragan Cicic | Senior Vice President & Chief Development Officer |
| Stacy Yeung | VP, General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 27, 2026 | 8-K | Current Report |
| Jun 25, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 4 | Filing |
| Jun 16, 2026 | S-8 | Filing |
SELLAS Life Sciences
| Country | United States |
| IPO Date | Mar 12, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Angelos Stergiou |
Contact Details
7 Times Square New York,
New York 10036 United States
Stock Details
| Ticker Symbol | SLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001390478 |
| CUSIP Number | 81642T209 |
| ISIN Number | US81642T2096 |
| SIC Code | 2834 |
Recent News
- 3 days ago / schaeffersresearch.comSellas Life Sciences Stock Jumps on Trial Results Timeline
- 4 days ago / globenewswire.comSELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- 13 days ago / globenewswire.comSELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
- 2 months ago / globenewswire.comSELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
- 3 months ago / globenewswire.comSELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
- 3 months ago / benzinga.comWhen Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
- 3 months ago / globenewswire.comSELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- 4 months ago / seekingalpha.comSELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up
- 4 months ago / benzinga.comSELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall
- 5 months ago / benzinga.comSELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?
Add to Watchlist
Select watchlists to add or remove SLS